{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:55:58Z","timestamp":1767192958424,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005633","name":"Syd\u00e4ntutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007417","name":"Paulon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007417","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003125","name":"Suomen Kulttuurirahasto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Finnish Governmental VTR-funding"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To explore long-term cardiovascular prognosis after myocardial infarction (MI) among patients with type 1 diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with type 1 diabetes surviving 90\u00a0days after MI (n\u2009=\u20091508; 60% male, mean age\u2009=\u200962.1\u00a0years) or without any type of diabetes (n\u2009=\u200962,785) in Finland during 2005\u20132018 were retrospectively studied using multiple national registries. The primary outcome of interest was a combined major adverse cardiovascular event (MACE; cardiovascular death, recurrent MI, ischemic stroke, or heart failure hospitalization) studied with a competing risk Fine-Gray analyses. Median follow-up was 3.9\u00a0years (maximum 12\u00a0years). Differences between groups were balanced by multivariable adjustments and propensity score matching (n\u2009=\u20091401 patient pairs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Cumulative incidence of MACE after MI was higher in patients with type 1 diabetes (67.6%) compared to propensity score-matched patients without diabetes (46.0%) (sub-distribution hazard ratio [sHR]: 1.94; 95% confidence interval [CI]: 1.74\u20132.17; p\u2009&lt;\u20090.0001). Probabilities of cardiovascular death (sHR 1.81; p\u2009&lt;\u20090.0001), recurrent MI (sHR 1.91; p\u2009&lt;\u20090.0001), ischemic stroke (sHR 1.50; p\u2009=\u20090.0003), and heart failure hospitalization (sHR 1.98; p\u2009&lt;\u20090.0001) were higher in patients with type 1 diabetes. Incidence of MACE was higher in diabetes patients than in controls in subgroups of men and women, patients aged\u2009&lt;\u200960 and\u2009\u2265\u200960\u00a0years, revascularized and non-revascularized patients, and patients with and without atrial fibrillation, heart failure, or malignancy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with type 1 diabetes have notably poorer long-term cardiovascular prognosis after an MI compared to patients without diabetes. These results underline the importance of effective secondary prevention after MI in patients with type 1 diabetes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-022-01608-3","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T15:20:55Z","timestamp":1662477655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Long-term cardiovascular prognosis of patients with type 1 diabetes after myocardial infarction"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-3291","authenticated-orcid":false,"given":"Anne M.","family":"Kerola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-2853","authenticated-orcid":false,"given":"Anne Grete","family":"Semb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9498-364X","authenticated-orcid":false,"given":"Markus","family":"Juonala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8835-8116","authenticated-orcid":false,"given":"Antti","family":"Palom\u00e4ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-1327","authenticated-orcid":false,"given":"P\u00e4ivi","family":"Rautava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-1093","authenticated-orcid":false,"given":"Ville","family":"Kyt\u00f6","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"1608_CR1","doi-asserted-by":"publisher","first-page":"798","DOI":"10.2337\/diacare.29.04.06.dc05-1433","volume":"29","author":"SS Soedamah-Muthu","year":"2006","unstructured":"Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care. 2006;29:798\u2013804.","journal-title":"Diabetes Care"},{"key":"1608_CR2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2014.16425","volume":"313","author":"SJ Livingstone","year":"2015","unstructured":"Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008\u20132010. JAMA. 2015;313:37\u201344.","journal-title":"JAMA"},{"key":"1608_CR3","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.116.025961","volume":"135","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson AM, Miftaraj M, et al. Range of risk factor levels: control, mortality, and cardiovascular outcomes in type 1 diabetes mellitus. Circulation. 2017;135:1522\u201331.","journal-title":"Circulation"},{"key":"1608_CR4","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1161\/CIRCULATIONAHA.118.037454","volume":"139","author":"A Rawshani","year":"2019","unstructured":"Rawshani A, Rawshani A, Sattar N, Franzen S, McGuire DK, Eliasson B, et al. Relative prognostic importance and optimal levels of risk factors for mortality and cardiovascular outcomes in type 1 diabetes mellitus. Circulation. 2019;139:1900\u201312.","journal-title":"Circulation"},{"key":"1608_CR5","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.2337\/dc20-2388","volume":"44","author":"I Bebu","year":"2021","unstructured":"Bebu I, Keshavarzi S, Gao X, Braffett BH, Canty AJ, Herman WH, et al. Genetic risk factors for CVD in type 1 diabetes: the DCCT\/EDIC study. Diabetes Care. 2021;44:1309\u201316.","journal-title":"Diabetes Care"},{"key":"1608_CR6","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1007\/s00125-011-2247-9","volume":"54","author":"M Eliasson","year":"2011","unstructured":"Eliasson M, Jansson JH, Lundblad D, Naslund U. The disparity between long-term survival in patients with and without diabetes following a first myocardial infarction did not change between 1989 and 2006: an analysis of 6,776 patients in the Northern Sweden MONICA Study. Diabetologia. 2011;54:2538\u201343.","journal-title":"Diabetologia"},{"key":"1608_CR7","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1177\/2047487319901063","volume":"27","author":"V Ritsinger","year":"2020","unstructured":"Ritsinger V, Nystrom T, Saleh N, Lagerqvist B, Norhammar A. Heart failure is a common complication after acute myocardial infarction in patients with diabetes: a nationwide study in the SWEDEHEART registry. Eur J Prev Cardiol. 2020;27:1890\u2013901.","journal-title":"Eur J Prev Cardiol"},{"key":"1608_CR8","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1161\/CIRCOUTCOMES.111.964700","volume":"5","author":"K Smolina","year":"2012","unstructured":"Smolina K, Wright FL, Rayner M, Goldacre MJ. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes. 2012;5:532\u201340.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1608_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s001250050032","volume":"43","author":"H Lowel","year":"2000","unstructured":"Lowel H, Koenig W, Engel S, Hormann A, Keil U. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia. 2000;43:218\u201326.","journal-title":"Diabetologia"},{"key":"1608_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4244\/EIJV10I1A15","volume":"10","author":"LP Hoebers","year":"2014","unstructured":"Hoebers LP, Claessen BE, Woudstra P, DeVries JH, Wykrzykowska JJ, Vis MM, et al. Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus. EuroIntervention. 2014;10:90\u20136.","journal-title":"EuroIntervention"},{"key":"1608_CR11","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.amjcard.2004.01.050","volume":"93","author":"D Antoniucci","year":"2004","unstructured":"Antoniucci D, Valenti R, Migliorini A, Parodi G, Moschi G, Memisha G, et al. Impact of insulin-requiring diabetes mellitus on effectiveness of reperfusion and outcome of patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2004;93:1170\u20132.","journal-title":"Am J Cardiol"},{"key":"1608_CR12","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.2337\/dc22-0042","volume":"45","author":"AM Kerola","year":"2022","unstructured":"Kerola AM, Juonala M, Palomaki A, Semb AG, Rautava P, Kyto V. Case fatality of patients with type 1 diabetes after myocardial infarction. Diabetes Care. 2022;45:1657\u201365.","journal-title":"Diabetes Care"},{"key":"1608_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022883","volume":"10","author":"AM Kerola","year":"2021","unstructured":"Kerola AM, Palomaki A, Rautava P, Nuotio M, Kyto V. Sex differences in cardiovascular outcomes of older adults after myocardial infarction. J Am Heart Assoc. 2021;10: e022883.","journal-title":"J Am Heart Assoc"},{"key":"1608_CR14","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/gerona\/glab152","volume":"77","author":"V Kyto","year":"2022","unstructured":"Kyto V, Nuotio M, Rautava P. Sex difference in the case fatality of older myocardial infarction patients. J Gerontol A Biol Sci Med Sci. 2022;77:614\u201320.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1608_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","volume":"133","author":"PC Austin","year":"2016","unstructured":"Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133:601\u20139.","journal-title":"Circulation"},{"key":"1608_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the e-value. Ann Intern Med. 2017;167:268\u201374.","journal-title":"Ann Intern Med"},{"key":"1608_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.carrev.2021.08.018","volume":"38","author":"A Matetic","year":"2022","unstructured":"Matetic A, Doolub G, Bharadwaj A, Osman M, Biondi-Zoccai G, Ullah W, et al. Differential impact of type 1 and type 2 diabetes mellitus on outcomes among 1.4 million us patients undergoing percutaneous coronary intervention. Cardiovasc Revasc Med. 2022;38:83\u20138.","journal-title":"Cardiovasc Revasc Med"},{"key":"1608_CR18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ejhf.797","volume":"19","author":"AA Tajik","year":"2017","unstructured":"Tajik AA, Dobre D, Aguilar D, Kjekshus J, Zannad F, Dickstein K, et al. A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High-Risk MI Database. Eur J Heart Fail. 2017;19:635\u201342.","journal-title":"Eur J Heart Fail"},{"key":"1608_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ijcard.2006.07.156","volume":"119","author":"AM Svensson","year":"2007","unstructured":"Svensson AM, Dellborg M, Abrahamsson P, Karlsson T, Herlitz J, Duval SJ, et al. The influence of a history of diabetes on treatment and outcome in acute myocardial infarction, during two time periods and in two different countries. Int J Cardiol. 2007;119:319\u201325.","journal-title":"Int J Cardiol"},{"key":"1608_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12933-015-0300-6","volume":"14","author":"PK Bundhun","year":"2015","unstructured":"Bundhun PK, Li N, Chen MH. Adverse cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after percutaneous coronary intervention: a systematic review and meta-analysis. Cardiovasc Diabetol. 2015;14:135.","journal-title":"Cardiovasc Diabetol"},{"key":"1608_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.amjcard.2021.02.025","volume":"148","author":"S Biswas","year":"2021","unstructured":"Biswas S, Dinh D, Andrianopoulos N, Lefkovits J, Ajani A, Duffy SJ, et al. Comparison of long-term outcomes after percutaneous coronary intervention in patients with insulin-treated versus non-insulin treated diabetes mellitus. Am J Cardiol. 2021;148:36\u201343.","journal-title":"Am J Cardiol"},{"key":"1608_CR22","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.diabet.2020.09.001","volume":"46","author":"B Verges","year":"2020","unstructured":"Verges B. Cardiovascular disease in type 1 diabetes: a review of epidemiological data and underlying mechanisms. Diabetes Metab. 2020;46:442\u20139.","journal-title":"Diabetes Metab"},{"key":"1608_CR23","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1136\/heartjnl-2016-311050","volume":"103","author":"V Matuleviciene-Anangen","year":"2017","unstructured":"Matuleviciene-Anangen V, Rosengren A, Svensson AM, Pivodic A, Gudbjornsdottir S, Wedel H, et al. Glycaemic control and excess risk of major coronary events in persons with type 1 diabetes. Heart. 2017;103:1687\u201395.","journal-title":"Heart"},{"key":"1608_CR24","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.2337\/dc20-3104","volume":"44","author":"R Gubitosi-Klug","year":"2021","unstructured":"Gubitosi-Klug R, Gao X, Pop-Busui R, de Boer IH, White N, Aiello LP, et al. Associations of microvascular complications with the risk of cardiovascular disease in type 1 diabetes. Diabetes Care. 2021;44:1499\u2013505.","journal-title":"Diabetes Care"},{"key":"1608_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12933-021-01340-4","volume":"20","author":"EB Parente","year":"2021","unstructured":"Parente EB, Harjutsalo V, Forsblom C, Groop PH, FinnDiane Study G. The impact of central obesity on the risk of hospitalization or death due to heart failure in type 1 diabetes: a 16-year cohort study. Cardiovasc Diabetol. 2021;20:153.","journal-title":"Cardiovasc Diabetol"},{"key":"1608_CR26","volume":"38","author":"AS Lee","year":"2021","unstructured":"Lee AS, Twigg SM, Flack JR. Metabolic syndrome in type 1 diabetes and its association with diabetes complications. Diabet Med. 2021;38: e14376.","journal-title":"Diabet Med"},{"key":"1608_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12933-021-01255-0","volume":"20","author":"N Wu","year":"2021","unstructured":"Wu N, Bredin SSD, Jamnik VK, Koehle MS, Guan Y, Shellington EM, et al. Association between physical activity level and cardiovascular risk factors in adolescents living with type 1 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol. 2021;20:62.","journal-title":"Cardiovasc Diabetol"},{"key":"1608_CR28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2337\/dc19-2292","volume":"43","author":"I Bebu","year":"2020","unstructured":"Bebu I, Schade D, Braffett B, Kosiborod M, Lopes-Virella M, Soliman EZ, et al. Risk factors for first and subsequent CVD events in type 1 diabetes: the DCCT\/EDIC study. Diabetes Care. 2020;43:867\u201374.","journal-title":"Diabetes Care"},{"key":"1608_CR29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jacc.2015.05.054","volume":"66","author":"T Nystrom","year":"2015","unstructured":"Nystrom T, Holzmann MJ, Eliasson B, Kuhl J, Sartipy U. Glycemic control in type 1 diabetes and long-term risk of cardiovascular events or death after coronary artery bypass grafting. J Am Coll Cardiol. 2015;66:535\u201343.","journal-title":"J Am Coll Cardiol"},{"key":"1608_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1586\/14779072.2014.853615","volume":"12","author":"C Bernelli","year":"2014","unstructured":"Bernelli C, Chan J, Chieffo A. Drug-eluting stent outcomes in diabetes. Expert Rev Cardiovasc Ther. 2014;12:95\u2013109.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"1608_CR31","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.amjcard.2010.06.042","volume":"106","author":"I Akin","year":"2010","unstructured":"Akin I, Bufe A, Eckardt L, Reinecke H, Senges J, Richardt G, et al. Comparison of outcomes in patients with insulin-dependent versus non-insulin dependent diabetes mellitus receiving drug-eluting stents (from the first phase of the prospective multicenter German DES.DE registry). Am J Cardiol. 2010;106:1201\u20137.","journal-title":"Am J Cardiol"},{"key":"1608_CR32","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0002-9149(00)01163-2","volume":"86","author":"P Pajunen","year":"2000","unstructured":"Pajunen P, Taskinen MR, Nieminen MS, Syvanne M. Angiographic severity and extent of coronary artery disease in patients with type 1 diabetes mellitus. Am J Cardiol. 2000;86:1080\u20135.","journal-title":"Am J Cardiol"},{"key":"1608_CR33","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1177\/2047487316687860","volume":"24","author":"V Ritsinger","year":"2017","unstructured":"Ritsinger V, Hero C, Svensson AM, Saleh N, Lagerqvist B, Eeg-Olofsson K, et al. Mortality and extent of coronary artery disease in 2776 patients with type 1 diabetes undergoing coronary angiography: a nationwide study. Eur J Prev Cardiol. 2017;24:848\u201357.","journal-title":"Eur J Prev Cardiol"},{"key":"1608_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108822","volume":"177","author":"I Johansson","year":"2021","unstructured":"Johansson I, Norhammar A. Diabetes and heart failure notions from epidemiology including patterns in low-, middle- and high-income countries. Diabetes Res Clin Pract. 2021;177: 108822.","journal-title":"Diabetes Res Clin Pract"},{"key":"1608_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/XCE.0000000000000166","volume":"8","author":"H Mamet","year":"2019","unstructured":"Mamet H, Petrie MC, Rocchiccioli P. Type 1 diabetes mellitus and coronary revascularization. Cardiovasc Endocrinol Metab. 2019;8:35\u20138.","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"1608_CR36","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41569-020-0339-2","volume":"17","author":"Y Tan","year":"2020","unstructured":"Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17:585\u2013607.","journal-title":"Nat Rev Cardiol"},{"key":"1608_CR37","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12933-021-01328-0","volume":"20","author":"AS Shah","year":"2021","unstructured":"Shah AS, Isom S, Dabelea D, D\u2019Agostino R Jr, Dolan LM, Wagenknecht L, et al. A cross sectional study to compare cardiac structure and diastolic function in adolescents and young adults with youth-onset type 1 and type 2 diabetes: the SEARCH for Diabetes in Youth Study. Cardiovasc Diabetol. 2021;20:136.","journal-title":"Cardiovasc Diabetol"},{"key":"1608_CR38","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1111\/bph.14993","volume":"177","author":"C Penna","year":"2020","unstructured":"Penna C, Andreadou I, Aragno M, Beauloye C, Bertrand L, Lazou A, et al. Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols. Br J Pharmacol. 2020;177:5312\u201335.","journal-title":"Br J Pharmacol"},{"key":"1608_CR39","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1161\/CIRCULATIONAHA.118.036068","volume":"139","author":"GR Sousa","year":"2019","unstructured":"Sousa GR, Pober D, Galderisi A, Lv H, Yu L, Pereira AC, et al. Glycemic control, cardiac autoimmunity, and long-term risk of cardiovascular disease in type 1 diabetes mellitus. Circulation. 2019;139:730\u201343.","journal-title":"Circulation"},{"key":"1608_CR40","doi-asserted-by":"publisher","unstructured":"Gottumukkala RV, Lv H, Cornivelli L, Wagers AJ, Kwong RY, Bronson R, et al. Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes. Sci Transl Med. 2012. https:\/\/doi.org\/10.1126\/scitranslmed.3003551.","DOI":"10.1126\/scitranslmed.3003551"},{"key":"1608_CR41","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1177\/2047487319861219","volume":"27","author":"SL Chan","year":"2020","unstructured":"Chan SL, Edwards NJ, Conell C, Ren X, Banki NM, Rao VA, et al. Age, race\/ethnicity, and comorbidities predict statin adherence after ischemic stroke or myocardial infarction. Eur J Prev Cardiol. 2020;27:2299\u2013301.","journal-title":"Eur J Prev Cardiol"},{"key":"1608_CR42","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0195-668X(02)00828-X","volume":"24","author":"A Norhammar","year":"2003","unstructured":"Norhammar A, Malmberg K, Ryden L, Tornvall P, Stenestrand U, Wallentin L, et al. Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J. 2003;24:838\u201344.","journal-title":"Eur Heart J"},{"key":"1608_CR43","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255\u2013323.","journal-title":"Eur Heart J"},{"key":"1608_CR44","first-page":"132","volume":"12","author":"P Pajunen","year":"2005","unstructured":"Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Raiha P, Karja-Koskenkari P, et al. The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2005;12:132\u20137.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"1608_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/1403494819847051","volume":"48","author":"MA Vuori","year":"2020","unstructured":"Vuori MA, Laukkanen JA, Pietila A, Havulinna AS, Kahonen M, Salomaa V, et al. The validity of heart failure diagnoses in the Finnish Hospital Discharge Register. Scand J Public Health. 2020;48:20\u20138.","journal-title":"Scand J Public Health"},{"key":"1608_CR46","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/01.hjr.0000239466.26132.f2","volume":"14","author":"H Tolonen","year":"2007","unstructured":"Tolonen H, Salomaa V, Torppa J, Sivenius J, Immonen-Raiha P, Lehtonen A, et al. The validation of the Finnish Hospital Discharge Register and Causes of Death Register data on stroke diagnoses. Eur J Cardiovasc Prev Rehabil. 2007;14:380\u20135.","journal-title":"Eur J Cardiovasc Prev Rehabil"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01608-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01608-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01608-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T16:02:56Z","timestamp":1662480176000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01608-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1608"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01608-3","relation":{},"ISSN":["1475-2840"],"issn-type":[{"type":"electronic","value":"1475-2840"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"20 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Please see \u201c\u201d under Methods.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AK: speaker fees from Boehringer-Ingelheim and Sanofi, advisory board fees from Pfizer, Gilead, and Boehringer-Ingelheim, and congress sponsorship from Pfizer, Celgene, UCB Pharma, Mylan, and Roche. AGS: speaker honoraria and\/or consulting fees from Pfizer, Amgen, Sanofi, Novartis, Bayer, AbbVie, and Lilly, unrestricted research grant from Lilly. MJ: speaker fees from Boehringer-Ingelheim, AstraZeneca, and Amgen. AP: consulting fees from Pfizer, AbbVie, and Amgen, lecture fees from MSD, Pfizer, and Sanofi, and travel expenses from Bristol Myers Squib and Novartis. PR: None. VK: scientific consultancy fees from AstraZeneca, speaker fee from Bayer, and travel grants and congress sponsorships from Bayer and Biotronic.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}